Skip to content
Mendelspod Podcast cover art

All episodes

Mendelspod Podcast, 582 episodes. Page 6 of 6.

#
Title
501

The Business of Aging and Three Reasons Why the FDA Drug Approval Rate Is So High

502

New York Genome Center’s Nathan Pearson on Public Outreach for Genomics

503

Tim Triche on Using Arrays for Cancer Research

504

Thermo’s Chris Linthwaite on Sequencing the Ebola Virus and the Future of Public Health

505

A Tool to Strengthen the Voice of Science in Online Journalism

506

Father of Child with Rare Disease Says Science Equals Medicine

507

Bina CEO Details Secret to Success in NGS Informatics

508

Cancer Researcher Tim Triche on the Staying Power of Microarrays

509

Want Answers? Look to the Non-Coding Region of the Genome, Says Cancer Researcher, Tim Triche

510

Ivan Oransky on Today's Retraction Boom

511

Genomics-Palooza, Diagnostics Fraud, and Biblical Prophets on the Future of Biotech

512

Ethical Issues around Editing Human Germline for the Future. Today It's about Plants and Animals, Says NYU's Art Caplan

513

We Got Research, PCSK9 Inhibitors, and Clinical Trials for Religion

514

The Multi-Platform Approach to Clinical Sequencing with Bobby Sebra, Icahn School

515

So That Happened, The Mad Genius, and Selling SynBio

516

Summer Genomics Festival, the Other Sports Genes, and Brain Surgery for Fruit Flies

517

The Sports Genes with Jeremy Koenig, Athletigen

518

Woodstock for Genomics? Richard Lumb and Carl Smith on this Month’s Festival

519

Geneticists Anonymous, the Sad State of Science Journalism, and New Kids on the Helix

520

The 9 Billion People Problem: Rod Wing on Plant Genomics

521

Should We Hold Back the Reins on Biotechnology? with Chris Gunter

522

Are We Ready to Trust Liquid Biopsies? with Milena Cankovic, Henry Ford Hospital

523

Gene and Tonic: Boxing for Cancer, Dubious Correlations, and When Should a Researcher Retire

524

New Patient Focused Genome Magazine Signing up Many Doctors Too

525

Gene and Tonic: The Decline of Pseudoscience, An Atheist for President, and What to Do with a Sexist Reviewer

526

Gene and Tonic: Sexism in Science, How to Spend an NIH Budget Increase, How Not to Spend It

527

Participation in Genomics Research a 21st Century Public Good, Says Paul Billings of Omicia

528

Gene and Tonic: Competition for 23andMe, Four Tips for Attending AACR 2015, and "Swab Stories"

529

Improving the Backbone of Clinical Genomics : Valerie Schneider, NCBI

530

Gene and Tonic: The ACA Turns Five, Ten Reasons to Have Your Genome Sequenced, and Humbled by the Ancients

531

Behind the Sequencing Bench with Dale Yuzuki

532

Gene and Tonic: The Tenth Commandment of Science, Icelandic Treasure, and TechBio Babies

533

It’s Pretty Bad: Andy Brooks of RUCDR on Sample Quality

534

Knowing More about What We Don’t Know: John McPherson on Cancer Genomics

535

Gene and Tonic: The iWatch and Research Kit, 23andMe Goes for the Big Time, No Spaceship

536

In Partnership with IBM’s Watson, Pathway Genomics Reinvents Itself

537

Affymetrix CEO, Frank Witney, on Arrays in the Age of Sequencing

538

Gene & Tonic: Disruption in Sequencing, Scientist Politicians, Some Cool Synbio

539

Changing the World with Color Changing Flowers

540

Cancer Researcher at Mayo Says Illumina Platform Maxing Out, Looks to BGI/Complete

541

Returning to Old Biotech Model, OncoMed Boasts of Seven Drugs in Clinical Trials by Mid 2015

542

Cutting through the Hype in Healthcare Innovation with David Shaywitz and Lisa Suennen

543

A Call to Consumers to Lead the Shift in Healthcare: Sharon Terry, Genetic Alliance

544

In Autoimmune Disease, Finding Clarity Beyond the Genome: Stefan Muellner, Protagen

545

Myriad Settlements Mark End of an Era: Antoinette Konski on Gene Patents

546

David Schwartz on the Future of Sequencing

547

Not a Stenographer to Power: Luke Timmerman and the New 'Timmerman Report'

548

FDA Will Take Time to Digest Comments on LDT Guidance, Says Liz Mansfield

549

Future of Personalized Medicine at Stake, says Amy Miller of PMC about LDT Regulation

550

'A Good Year' with John LaMattina

551

An Exciting Time for Mass Spec: Paul Beresford, Biodesix

552

Current Version of LDT Draft Guidance Means Much Fewer and Lower Quality Tests for Patients, Says Elaine Lyon of ARUP

553

The Sad State of Biospecimen Science with David Rimm, Yale

554

Cancer 2014: The Year in Review with Anna Barker

555

Faces of Leadership in Diagnostics: Surbhi Sarna

556

Historic Consensus Reached on Biospecimen Standards: Carolyn Compton, NBDA

557

Setting Better Expectations for Genomic Medicine: Geoff Ginsburg, Duke University

558

Test Driving Genomic Medicine: Thomas Quertermous, Stanford

559

The Silicon Valley Fantasy Trip: Sci-fi Author Kim Stanley Robinson Talks Life Science

560

Faces of Leadership in Diagnostics: Mara Aspinall

561

The Daunting Task of Managing Biospecimens at the World's Largest CRO: Diane Farhi, Quintiles

562

Janet Woodcock, FDA, on Biomarker Development and the Future of Clinical Trials

563

Biosampling Basics with Scott Jewell, Van Andel Institute

564

Faces of Leadership in Diagnostics: Bonnie Anderson, Veracyte

565

Biotech’s Gentleman Lawyer: Alan Mendelson

566

The Open Secret about the HER2 Assay with Jim Vaught

567

What a Physicist Can Tell Us about Cancer

568

'Moving Target Science:' Jonathan Brody on Pancreatic Cancer

569

The Progress of Clinical Genomics in Sweden with Ulf Gyllensten

570

Proteins Are Where It's At: Chip Petricoin, George Mason University

571

After a Decade on the Sidelines, Gene Myers Back into Sequencing, Excited about Long Reads

572

The Story of Aubrey de Grey and How the Study of Aging Became Mainstream

573

#ScienceHack with Connor Dickie, Synbiota

574

What Translational Gap? Michael Pishvaian on Advances in Tumor Profiling

575

A Dangerous Book? Science Historian Nathaniel Comfort Discusses “A Troublesome Inheritance”

576

Eric Schadt on Long Read Sequencing and Clinical Genomics

577

George Church at 60

578

Major Sequencing Projects Should Be Done with Long Reads, Says Dan Geraghty

579

Test Driving Illumina's X Ten with Shawn Baker, AllSeq

580

Short Read Sequencing Not Up to the Task of Characterizing Transcriptome Says Mike Snyder of Stanford

581

U.K. Life Science Update with Eliot Forster, MedCity

582

Paperwork, Not Algorithms the Biggest Challenge for Large Bioinformatics Projects, Says David Haussler, UCSC

583

Big Pharma Does Some Farming: Pearl Huang, GSK